- Home
- CALC vs RLMD Comparison
CALC vs RLMD Comparison
Compare CALC & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CALC
- RLMD
- Stock Information
- Founded
- CALC 2011
- RLMD 2004
- Country
- CALC United States
- RLMD United States
- Employees
- CALC 15
- RLMD N/A
- Industry
- CALC Biotechnology: Pharmaceutical Preparations
- RLMD Biotechnology: Pharmaceutical Preparations
- Sector
- CALC Health Care
- RLMD Health Care
- Exchange
- CALC Nasdaq
- RLMD Nasdaq
- Market Cap
- CALC 22.9M
- RLMD 22.0M
- IPO Year
- CALC N/A
- RLMD N/A
- Fundamental
- Price
- CALC $1.43
- RLMD $0.67
- Analyst Decision
- CALC Strong Buy
- RLMD Buy
- Analyst Count
- CALC 3
- RLMD 3
- Target Price
- CALC $16.33
- RLMD $5.00
- AVG Volume (30 Days)
- CALC 22.6K
- RLMD 478.7K
- Earning Date
- CALC 08-11-2025
- RLMD 08-06-2025
- Dividend Yield
- CALC N/A
- RLMD N/A
- EPS Growth
- CALC N/A
- RLMD N/A
- EPS
- CALC N/A
- RLMD N/A
- Revenue
- CALC N/A
- RLMD N/A
- Revenue This Year
- CALC N/A
- RLMD N/A
- Revenue Next Year
- CALC N/A
- RLMD N/A
- P/E Ratio
- CALC N/A
- RLMD N/A
- Revenue Growth
- CALC N/A
- RLMD N/A
- 52 Week Low
- CALC $1.43
- RLMD $0.24
- 52 Week High
- CALC $5.97
- RLMD $4.47
- Technical
- Relative Strength Index (RSI)
- CALC 32.78
- RLMD 52.84
- Support Level
- CALC $1.48
- RLMD $0.67
- Resistance Level
- CALC $1.79
- RLMD $0.72
- Average True Range (ATR)
- CALC 0.12
- RLMD 0.08
- MACD
- CALC -0.02
- RLMD -0.03
- Stochastic Oscillator
- CALC 0.00
- RLMD 40.29
About CALC CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.